A randomized phase II trial of 5-fluorouracil, with or without human interferon-β, for advanced colorectal cancer

por Villar-Grimalt, A, Candel, M T, Massuti, B, Lizón, J, Sánchez, B, Frau, A, Gorostidi, B, Goedkoop, R
Publicado 1999

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015

por García-Campelo, R., Bernabé, R., Cobo, M., Corral, J., Coves, J., Dómine, M., Nadal, E., Rodriguez-Abreu, D., Viñolas, N., Massuti, B.
Publicado 2015

UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy

por Martinez-Balibrea, E, Abad, A, Martínez-Cardús, A, Ginés, A, Valladares, M, Navarro, M, Aranda, E, Marcuello, E, Benavides, M, Massutí, B, Carrato, A, Layos, L, Manzano, J L, Moreno, V
Publicado 2010

First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumo...

por Carrato, A., Benavides, M., Massutí, B., Ferreiro-Monteagudo, R., García Alfonso, P., Falcó, E., Reboredo, M., Cano, T., Gallego, J., Viéitez, J. M., Layos, L., Salud, A., Polo, E., Dotor, E., Durán-Ogalla, G., Rodriguez-Garrote, M., Calvo, A., Grande, E., Aranda, E.
Publicado 2019